NANOCAN

Nanocan Therapeutics Corporation is an early-stage biotechnology company developing novel drug-delivery nanotechnology for more precise and targeted treatment of cancer and respiratory diseases. More precise local treatment can unlock local immune-driven potential and significantly reduce the risk of side effects. Through our partnerships with leading academic research institutions, we are rapidly developing new shorter and efficient combination therapies to help improve the lives of patients and improve global access to care... Nanocan is committed to making its disruptive innovations for shorter one-day delivery of combinations of radiotherapy and immunotherapy, available to cancer patients in Low and Middle-Income Countries ("LMICs"), starting with countries in Africa through our strong network of leading US and UK universities, as well as partners in Nigeria, Kenya, South Africa. Nanocan is simultaneously pursuing clinical trials and regulatory approvals in both the U.S. and..

Also known as: Nanocan Therapeutic Corporation, Nanocan Therapeutic Corporation, Inc., Nanocan Therapeutics Corporation

Primary location: Princeton United States